FY2026 · ended Mar 31, 2026 · Revenue $148.87M, +77.1% YoY · Filed Jun 29, 2026
Elite Pharmaceuticals, Inc. (ELTP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $148.9 million and net income of $44.9 million. Free cash flow was $22.8 million. As of Jun 30, 2026 it held $38.9 million in cash and investments and $2.6 million in total debt.
Revenue (TTM)
$141.01M
+33.7% vs year-ago TTM
Net income (TTM)
$56.67M
+624.0% vs year-ago TTM
Operating cash flow (TTM)
$19.04M
-0.2% vs year-ago TTM
Free cash flow (TTM)
$17.53M
-2.8% vs year-ago TTM
EPS (TTM)
$0.05
+584.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.08B
+0.8% vs prior year
Net cash
$36.38M
as of Jun 30, 2026
Operating margin
24.8%
FY 2027
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTP (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NJ
- Headquarters
- Northvale, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053369
- Former names
- ELITE PHARMACEUTICALS INC /DE/ (until Feb 8, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M | $32.3M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.7M | $5.1M |
| Net income | $44.9M | -$4.3M | $20.1M | $3.6M | $8.9M |
| Diluted EPS | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 |
| Operating cash flow | $23.7M | $7.5M | -$3.2M | $3.3M | $6.5M |
| Free cash flow | $22.8M | $5.8M | -$4.0M | -$2.4M | — |
| Total assets | $138.3M | $96.4M | $83.7M | $40.9M | $35.1M |
| Total liabilities | $39.4M | $42.9M | $26.1M | $11.9M | $9.9M |
| Stockholders' equity | $98.9M | $53.5M | $57.6M | $29.0M | $25.2M |
| Cash and investments | $29.8M | $11.3M | $7.1M | $7.8M | $8.5M |
| Total debt | $2.8M | $3.6M | $4.2M | $14,914 | $2.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 3, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Regulation FD disclosure
|
Aug 11, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
All 1000 Elite Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.